Pediapred Should NOT Be Used for Influenza in Infants
Corticosteroids like Pediapred (prednisolone) are contraindicated for treating influenza in infants and should be avoided. The evidence consistently demonstrates harm rather than benefit, and current guidelines explicitly recommend against their use.
Why Corticosteroids Are Harmful in Influenza
The most recent WHO clinical practice guidelines (2024) and AAP recommendations (2025-2026) make conditional recommendations AGAINST corticosteroid use in severe influenza 1, 2, 3. This is based on substantial evidence showing:
- Increased mortality: Meta-analyses demonstrate corticosteroid therapy is associated with significantly increased death rates (OR 3.90,95% CI 2.31-6.60) and adjusted hazard ratios showing 49% increased mortality risk 4, 5
- Higher infection rates: Hospital-acquired infections increase nearly 3-fold (OR 2.74,95% CI 1.51-4.95) with corticosteroid use 4
- Prolonged illness: Mechanical ventilation duration increases by 3.82 days and ICU stays lengthen by 4.78 days 6
- Delayed viral clearance: Corticosteroids impair the body's ability to eliminate influenza virus 7
These findings are consistent across multiple systematic reviews spanning 2015-2025 4, 5, 6, 7.
What Should Be Used Instead
Oseltamivir is the preferred antiviral for infants with influenza 8, 9. The AAP and CDC guidelines specify:
For Infants (Birth to <12 months):
- Term infants: Oseltamivir is FDA-approved from 2 weeks of age and can be used from birth based on pharmacokinetic data showing benefits outweigh risks 8, 9
- Dosing varies by age:
- 0-8 months: 3.0 mg/kg twice daily
- 9-11 months: 3.5 mg/kg twice daily (higher than FDA-approved dose, based on AAP data) 9
- Preterm infants: Lower weight-based dosing using postmenstrual age; consult pediatric infectious disease for extremely preterm infants (<28 weeks) 9
Treatment Indications for Infants:
Antiviral treatment should be started as early as possible (ideally within 48 hours, but no time limit for severe cases) for 8, 9:
- Any hospitalized infant with suspected/confirmed influenza
- Any infant with severe, complicated, or progressive disease
- All infants <5 years are considered high-risk and should receive treatment regardless of severity
Critical Distinction: COVID-19 vs. Influenza
A crucial pitfall to avoid: corticosteroids show benefit in severe COVID-19 but cause harm in influenza 7, 10. The RECOVERY trial demonstrated dexamethasone reduces mortality in severe COVID-19, but this finding does NOT apply to influenza. The opposing outcomes reflect distinct immunopathological mechanisms between these viral infections 7.
Pediapred-Specific Concerns in Infants
The FDA label for Pediapred highlights additional pediatric safety concerns 11:
- Growth suppression: Even low systemic doses can decrease growth velocity in children, often without laboratory evidence of HPA axis suppression
- Immunosuppression: Diminished response to vaccines and increased risk of infection from live attenuated vaccines
- Multiple adverse effects: Increased risk of infections, metabolic disturbances, and other complications that are particularly concerning in the vulnerable infant population
Bottom Line Algorithm
For any infant with suspected or confirmed influenza:
- Start oseltamivir immediately (age-appropriate dosing)
- Do NOT give corticosteroids (including Pediapred)
- Consider hospitalization if <5 years with any concerning features
- Test with RT-PCR or NAAT if hospitalized 9
- Monitor for bacterial superinfection (antibiotics only if documented bacterial co-infection) 8
The evidence is clear and consistent: corticosteroids worsen outcomes in influenza across all age groups, and this is especially critical to avoid in vulnerable infant populations.